Back to Resources
Market Highlights
- In Q3 2025, all brands in the Cushing’s disease market maintained a digital presence through social media and websites. Marketing primarily targeted healthcare professionals, with digital formats favored over print. Educational campaigns, clinical progress, product positioning, and expanded patient support were key areas of focus.
- Corcept ran educational ad on its Korlym and Cushing’s Connection pages to raise awareness of excess cortisol and its health effects. The company continued promoting Korlym through the “Ease the Grip” campaign and introduced relacorilant as an investigational GR modulator aimed at addressing cardiovascular risks with potentially fewer side effects.
- Crinetics shared clinical updates and marked milestones, including ringing the Nasdaq Opening Bell and unveiling a redesigned website. It positioned Atumelnant as a next-generation therapy built on its GPCR drug discovery platform.
- Recordati promoted Isturisa’s rapid cortisol normalization, flexible dosing, and expanded patient support through the R.A.R.E. program.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com